Reneural Technologies Limited, formerly known as CardioCrown, has secured £475,000 to advance its neurorehabilitation platform for stroke survivors.
The firm based in Hatfield, Hertfordshire is addressing the critical gap in effective and continuous rehabilitation with its innovative approach to enhance patient outcomes, reduce clinician burnout and lower healthcare costs.
The company facilitates early discharge from hospitals, improves patient engagement and compliance, while enabling efficient remote care.
With this funding, ReneuralTM plans to grow its VR therapy offerings and expand into mental health support for stroke survivors. The company’s long-term vision is to become a leader in neurorehabilitation, using innovative technologies to improve patient outcomes while reducing the strain on healthcare systems.
The funding round was led by SFC Capital, alongside undisclosed investors, and was completed in conjunction with Innovate UK’s Investor Partnerships SME Round 7.
“We’re excited to have led the investment into Reneural and to support the team on their journey to improve rehabilitation for stroke survivors,” said Ed Stevenson, investment executive at SFC Capital.
“What really impressed us was their passion for tackling this problem, and we’re looking forward to seeing their impact on patient outcomes through their new VR products and mental health support.”
Co-founders Victor Harabari (CEO) and Heraldas Gaspariunas (COO) stated: “We are excited to have such an incredible group of investors supporting our mission to leverage technology in transforming healthcare delivery, improving access, quality, and efficiency for both patients and clinicians.”
Reneural has made significant advances in development, with support from Innovate UK’s FastTrack programme in November 2022, securing £50K to build the proof of concept for its neurorehabilitation platform. The first clinical investigations are set to take place in January 2025 with support from HTCC SME Accelerators in partnership with University of Hertfordshire.
The company is working closely with healthcare professionals and experts to ensure the platform’s success and adoption across clinical pathways, both in hospital settings and at home.
£52m tech development launched in Harley Street Health District